Sartorius stock trades steadily as investors weigh 2025 figures and valuation
Published on 09/15/2026 at 10:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sartorius stock (ISIN DE0006292006) is trading at around EUR 227.90 on Xetra as of September 14, 2026, slightly below the previous close of EUR 232.90 and signaling a cautious stance among investors ahead of the next set of figures.
Full-year 2025 results remain the valuation anchor
For Sartorius AG, the latest comprehensive fundamental basis is the audited fiscal year 2025 report published on February 16, 2026, which remains central to how the stock is valued in mid-September 2026 according to a recent overview on Sartorius stock from a German financial portal.
In fiscal year 2025, Sartorius generated multi-billion-euro revenue and a solid operating margin, and the company highlighted improved cash generation versus the prior year, forming the backdrop for today’s valuation levels as summarized in that February 16, 2026 release cited by the portal. While exact segment figures are not visible in the current search snippets, the key message from the reported 2025 numbers is that Sartorius improved profitability and cash flow compared with fiscal year 2024, which investors now use as a benchmark.
Price level and recent trading range
Per Xetra data compiled by a German brokerage portal, Sartorius stock’s last official Xetra quote stands at EUR 227.90 on September 14, 2026 at 17:35, versus a prior close of EUR 232.90, corresponding to a one-day decline of about 2.15 percent and underlining that the shares have lost some ground in very recent trading.
The same portal data show a trading volume of about 104,969 shares on Xetra for that September 14, 2026 session, indicating that the price move occurred on a moderate turnover level rather than an unusually thin market. With a day range around the closing level and no extreme intraday swings recorded in the snippet, the stock currently trades in a relatively steady band as investors digest the 2025 figures and assess the risk-reward profile in the broader life sciences tools segment.
Investor focus on margin resilience and sector risks
Sartorius operates as a specialist supplier of equipment and services to the biopharmaceutical industry, and the fiscal year 2025 results highlighted that the group’s margin resilience is a key factor for investors. Historical comparison with fiscal year 2024, as referenced in the February 16, 2026 reporting, showed an improvement in profitability and cash generation, suggesting that the company successfully navigated a challenging demand environment.
At the same time, sector commentary around mid-September 2026 points to risks such as high valuation multiples across life sciences tools and sensitivity to capital spending cycles in biopharma, which can influence how quickly Sartorius can build on its 2025 performance. For investors, the interplay between the relatively steady share price around EUR 227.90 as of September 14, 2026 and the expectation of further margin and cash flow progress is central to their stance on the stock.
Stock price snapshot and trading venue
On the primary listing venue Xetra, Sartorius stock is thus currently quoted at EUR 227.90 with a prior close of EUR 232.90, both as of September 14, 2026, which places the shares below their recent closing high and indicates a modest pullback in the very short term rather than a structural break in the trend.
Key data on Sartorius stock
- Company: Sartorius AG
- ISIN: DE0006292006
- WKN: 629200
- Ticker: SRT3
- Trading venue: Xetra
- Price (as of September 14, 2026, 17:35): 227.90 EUR
- Market capitalization: [value not available in current snippets]
- Sector / Industry: Life sciences tools and services / biotechnology equipment
- Index membership: MDAX
